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Abstract
Background: “Phosphatase and tensin homolog deleted on chromosome 10” (PTEN) is mostly considered to be a
cancer-related gene, and has been suggested to be a new pathway of pathogenesis of asthma. The purpose of
this study was to investigate the effects of the glucocorticoid, dexamethasone, on PTEN regulation.
Methods: OVA-challenged mice were used as an asthma model to investigate the effect of dexamethasone on
PTEN regulation. Immunohistochemistry was used to detect expression levels of PTEN protein in lung tissues. The
human A549 cell line was used to explore the possible mechanism of action of dexamethasone on human PTEN
regulation in vitro. A luciferase reporter construct under the control of PTEN promoter was used to confirm
transcriptional regulation in response to dexamethasone.
Results: PTEN protein was found to be expressed at low levels in lung tissues in asthmatic mice; but the
expression was restored after treatment with dexamethasone. In A549 cells, human PTEN was up-regulated by
dexamethasone treatment. The promoter-reporter construct confirmed that dexamethasone could regulate human
PTEN transcription. Treatment with the histone deacetylase inhibitor, TSA, could increase PTEN expression in A549
cells, while inhibition of histone acetylase (HAT) by anacardic acid attenuated dexamethasone-induced PTEN
expression.
Conclusions: Based on the data a new mechanism is proposed where glucocorticoids treat asthma partly through
up-regulation of PTEN expression. The in vitro studies also suggest that the PTEN pathway may be involved in
human asthma.
Background
Bronchial asthma is a chronic inflammatory disorder of
the airways, with episodic occurrences of airflow
obstruction, and hypersensitivity and hyperresponsive-
ness to various stimuli. Asthma is one of the most com-
mon diseases, occurring in approximately 300 million
people of all ages and ethnic backgrounds worldwide
[1,2]. Many attempts have been made over decades to
discover the etiology of the disease, and thousands of
papers have been published. Although the mechanism is
still not well understood, inflammation has been identi-
fied as the main reason that could explain most of the
symptoms of asthma [3,4].
Because the dominant pathological feature is airway
inflammation, one of the main achievements of the last
decade has been the understanding of the inflammation
nature of the disease [4,5]. In view of the unclear etiol-
ogy of asthma, the purpose of asthma treatment is to
achieve and maintain clinical control. Although the
guidelines for asthma management by the Global Initia-
t i v ef o rA s t h m a( G I N A )h a v eg o n et h r o u g hm a n yr e v i -
sions since 1989 [6], the status of corticosteroids in this
management has been stable because of their most
effective anti-inflammatory function. Inhaled glucocorti-
coids are the most effective control currently available.
Systemic administration of glucocorticoids are com-
monly used in the treatment of severe acute exacerba-
tions because they prevent the progression of asthma
exacerbation, reduce the need for referral to emergency
departments and hospitalization, prevent early relapse
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the illness. The mechanism of glucocorticoids in asthma
therapy has been explored for decades. Genomic and
non-genomic mechanisms have been reviewed recently
by Alangari [7], and more efforts are still being made to
further our understanding of the mechanisms to help
with application to therapeutics.
The PTEN (Phosphatase and tensin homolog deleted
on chromosome 10) gene has been identified as one of
the most commonly lost or mutated tumor suppressor
genes in humans. It functions as a plasma-membrane
lipid phosphatase that antagonizes the PI3K (phosphoi-
nositide 3 kinase)-AKT pathway. PTEN exerts a wide
range of effects on cell growth, migration, death, and dif-
ferentiation[8]. The gene has drawn interest concerning
its potential role in asthma in recent years. It has been
confirmed that PTEN expression is down-regulated in an
asthma model, and that exogenous PTEN can effectively
relieve asthma in these mice [9-11], and reduce chronic
airway inflammation and airway remodeling through reg-
ulation of IL-17 expression [12]. Administration of per-
oxisome proliferator-activated receptor gamma
(PPARgamma) agonists or AdPPARgamma reduced
bronchial inflammation and airway hyperresponsiveness
by up-regulating PTEN expression in allergen-induced
asthmatic lungs [13]. It has been found recently that
PTEN can inhibit human airway smooth muscle cell
migration [14] as well as endothelial nitric oxide synthase
[15], which, in turn, inhibit airway inflammation. Because
of these facts, PTEN has been proposed as a therapeutic
target for asthma [16]. PTEN acts as the catalytic antago-
nist of PI3K by dephosphorylating PIP3 to PIP2. PI3K-
beta, delta and gamma isoform-specific PI3K inhibitors
(TGX-221, IC87114 and AS-605240) have been devel-
oped for asthma treatment [17].
The evidence for the involvement of PTEN in asthma
in humans, however, is rare. Moreover, there are no
available data on the effects of glucocorticoids on PTEN
expression. In this study, we discovered that dexametha-
sone could upregulate PTEN expression in mice and in
a human lung epithelial cell line. We also describe a
new signaling pathway for steroids in asthma.
Methods
OVA-induced mouse model of asthma
All experimental procedures conformed to international
standards of animal welfare, and were approved by the
Institute Animal Care and Use Committee of Shanghai
University of Traditional Chinese Medicine. Female
BALB/c mice were purchased from Shanghai SLAC
Laboratory Animal Co. Ltd. All mice were kept in well-
controlled animal housing facilities, and had free access
to tap water and food pellets throughout the experimen-
tal period. Female, 6-8-week-old BALB/c mice (n = 30)
were divided into three groups: OVA-treated group
(OVA-challenged mice treated with saline), OVA+dexa-
methasone-treated group (OVA-challenged mice treated
with dexamethasone) and a saline-group (saline-chal-
lenged mice treated with saline). Mice were challenged
with Ovalbumin (OVA) (Grade V; Sigma Aldrich,
Shanghai, China) by intraperitoneal and intranasal
routes. OVA treated (n = 10) and dexamethasone trea-
t e d( O V A / D M )( n = 10) groups were immunized by
intraperitoneal (i.p.) injections of 100 μg of OVA mixed
with potassium aluminum sulfate on days 0 and 14 [18].
Mice received an intranasal dose of 500 μgO V Ao n
days 14, 25, 26, 27. The control group (n = 10) received
normal saline with alum i.p. on days 0 and 14 and nor-
mal saline without alum intranasally on days 14, 25, 26,
27 [19]. The group of dexamethasone-treated mice was
administered with dexamethasone intraperitoneally (1.7
mg/kg, once a day) beginning on day 28 of the protocol
and continuing until day 41. Animals were sacrificed by
i.p. injection of pentobarbital at day 42, and the lungs
and extrahilar tracheobronchial airways were rapidly dis-
sected out.
Tissue processing and immunohistochemistry analysis
Immunohistochemistry detection of PTEN was done as
described elsewhere [9]. Tissue sections from the right
lungs were first treated with PTEN antibody (R&D Sys-
tems, Minneapolis, MN, USA). After incubation at 4°C
overnight, tissue sections were washed with PBS, and
treated with ligation enhancing buffer (Maixin Bio, FuZ-
hou, China)) for 30 min at room temperature. Tissue sec-
tions were then washed with PBS, and treated for 30 min
with horseradish peroxidase (HRP)-anti-rabbit IgG
(Maixin Bio). The color was developed using diamino-
benzidine (DAB). The intensity of PTEN protein staining
was determined as an average optical density by IPP soft-
ware (Image-Pro Plus 6.0, Media, Cybernetics). A non-
stained region was selected and set as the background.
Cell culture
The lung epithelial cell line, A549, was purchased from the
Institute of Cell Biology (Shanghai, China), and cultured in
RMPI1640 medium (Gibco, Shanghai, China) supplemen-
ted with 10% fetal bovine serum, penicillin and streptomy-
cin. A549 cells were treated with the indicated
concentrations of dexamethasone for 24 h. Otherwise, the
cells were treated with 1 × 10
-5 M dexamethasone. The
cells were harvested at 24 h, 48 h, 72 h, and 96 h.
PTEN expression analysis by real-time quantitative PCR
Total RNA from A549 cells were extracted by Trizol
(Invitrogen Life Technologics, Carlsbad, CA, USA). The
RNA (0.5 μg) was reverse transcribed to cDNA, using a
RevertAid First Strand cDNA Synthesis Kit (Fermentas,
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formed by Universal Master Mixer (Roche Applied
Science, Shanghai, China) on a 7300 Real-time PCR Sys-
tem (Applied Biosystems, Foster City, CA, USA). The
primers and probes used are listed in Table 1. Each
assay was performed in triplicate. The PCR conditions
used in all reactions were: 10 min at 95°C, followed by
40 two-step cycles (95°C for 15 s and 60°C for 45 s).
T h er e l a t i v ee x p r e s s i o nl e v e l so ft h eP T E Ng e n ew e r e
normalized against GAPDH and analyzed by the 2
-ΔΔCt
method [ΔΔCt = (Ct PTEN -C tGAPDH )sample -( C tPTEN
-C tGAPDH )control].
Reporter construct, transient transfections and luciferase
assays
The PTEN promoter sequence was amplified from
human blood cells. Primers were designed according to
human genomic PTEN (GenBank accession no.
AF067844, Table 1). To construct pGL3-PTEN, ampli-
fied DNA fragments were digested with Kpn I and Bgl
II, and subcloned into the pGL3-basic vector (Promega,
Madison, WI, USA). Before transfection, A549 cells
were plated in 24-well plates at a density of 50,000 cells/
well and grown overnight. Cells were co-transfected
with 0.8 μg/well of the pGL3-PTEN construct and 0.5
ng/well Renilla luciferase control plasmid (PRL-SV40)
by Lipofectmine 2000 (Invitrogen, Shanghai, China).
After 24 h, cells were treated with dexamethasone for
another 24 h. Luciferase activity was assayed by using a
dual-luciferase reporter assay system (Promega) on a
luminometer (GloMax 20/20, Promega).
Trichostatin A (TSA) and anacardic acid treatment
To analyze the relationship among dexamethasone, his-
tone acetylation and PTEN expression, the A549 cell
line was allowed to grow overnight to 70% confluency
in 6 well plates. The next day, TSA (Sigma, Shanghai,
China) were added directly to the cells to a final con-
centration of 1 μmol/L. An equivalent volume of vehicle
(DMSO) was added to the control. After a 24 h incuba-
tion, cells were harvested and total RNA was prepared
as described for RT-PCR analysis. In anacardic acid
(Sigma) experiments, cells were treated with dexametha-
sone (10
-5 M) alone or dexamethasone (10
-5 M) plus
anacardic acid (20 μmol/L) for 24 h.
Statistical analysis
Results were expressed as the mean ± SD. Variance ana-
lysis was used for statistical comparisons between
groups by Student’s t-test. Statistical significance was set
at p < 0.05.
Results
Restoration of PTEN expression in OVA-treated mice with
dexamethasone
The lung tissues in the dexamethasone treated groups
had a marked inhibition of OVA-induced inflammation
including lower infiltration of eosinophils and lympho-
cyte, decreased of airway smooth muscle thickening and
collagen deposition (Figure 1A-C), which are consistent
with published data [20,21]. Immunohistochemistry was
used to detect the PTEN protein expression level in
lung tissue. PTEN was expressed mainly in epithelial
Table 1 Sequences of primers and probes
Primers or Probes Sequence
Forward Primer
(PTEN)
5’-GGGACGAACTGGTGTAATGATATG-3’
Reverse Primer
(PTEN)
5’-ATAGCGCCTCTGACTGGGAATAG-3’
TaqMan Probe
(PTEN)
5’-fam- CCCTTTTTGTCTCTGGTCCTTACTTCCCC
-tamra-3’
Forward Primer
(GADPH)
5’-CCACTCCTCCACCTTTGAC-3’
Reverse Primer
(GADPH)
5’-ACCCTGTTGCTGTAGCCA-3’
TaqMan Probe
(GADPH)
5’-fam- TTGCCCTCAACGACCACTTTGTC -tamra-3’
PTEN promoter-F 5’-GGGGTACCGTGTATCCTTCCACCTCC-3’
PTEN promoter-R 5’-GAAGATCTGGCCTCGCCTCACAGCGGCTCAACTC-3’
Figure 1 Histological evidence of airway inflammation (A-C)
and PTEN expression determined by immunohistochemical
staining(D-F) and the arrows pointing to the epithelia cells.( A
and D): Lung tissue from mouse sensitized with saline. (B and E):
Lung tissue from mouse after sensitization with OVA. (C and F):
Lung tissue from mouse after sensitization with OVA, and treatment
with dexamethasone.
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noreactive PTEN protein was under-expressed in the
OVA-treated group compared with the saline control
groups (Figure 1E). However, when mice in the OVA-
treated group were treated with dexamethasone,
the PTEN expression in lung tissues was restored
(Figure 1F). The average optical density was measured
also (Figure 2). The OVA-treated group showed a signif-
icantly lower density compared with the saline group
(p = 0.007) and OVA plus dexamethasone (p = 0.008).
Dexamethasone promotes the expression of PTEN by
stimulating PTEN transcription
To further confirm the role of dexamethasone in PTEN
expression, human A549 lung epithelial cells were trea-
ted with dexamethasone at the concentration 10
-5 M-10
-
8 M for 24 h, or at the concentration 10
-5 Ma n dh a r -
vested at 24, 48, 72, 96 h. The expression of PTEN
m R N Aw a sa n a l y z e db yr e a l - t i m eP C R .A ss h o w ni n
Figure 3A and 3B, dexamethasone treatment increased
PTEN mRNA expression in a dose- and time-dependent
manner, indicating that the effects of dexamethasone on
PTEN expression might have occurred at the transcrip-
tional level. To confirm this hypothesis, the PTEN pro-
moter was cloned and constructed into the pGL3
luciferase plasmid, as described in the Methods section.
We found that dexamethasone (10
-5 M) treatment sig-
nificantly increased the PTEN promoter activity (Figure
3C), indicating that dexamethasone promoted the
expression of PTEN by stimulating PTEN transcription.
The effect of acetylation of histone on the regulation of
PTEN expression
As histone acetylation is one of the important mechanisms
for the effect of glucocorticoids [22], we hypothesized that
the regulation of PTEN expression by dexamethasone
might involve histone acetylation. We treated A549 cells
first with TSA, and confirmed that histone deacetylase
inhibition was associated with the up-regulation of PTEN
transcription (p = 0.006) (Figure 4), an observation that
was consistent with a previous report [23]. We then trea-
ted A549 cells with dexamethasone (10
-5 M) plus the his-
tone acetylase inhibitor anacardic acid (20 μmol/L) for 24
h. We extracted the total RNA and analyzed it by real-
time PCR. We found that dexamethasone (10
-5 M) alone
increased PTEN mRNA expression, whereas treatment
Figure 2 Immunohistochemistry analysis of PTEN protein by
average optical density (mean ± SD). Bars, 25 μm.
Figure 3 Effect of dexamethasone on PTEN regulation in A549
cells. A representative of three independent experiments is shown.
(A): A549 cells were treated with dexamethasone at the indicated
concentrations for 24 h. (B): A549 cells were treated with
dexamethasone (10
-5 M) for 24 h, 48 h, 72 h and 96 h. The PTEN
mRNA level was measured by quantitative real-time PCR. (C): A549
cells were transfected with the PTEN promoter luciferase plasmid for
24 h and treated with 10
-5 M dexamethasone for another 24 h. The
luciferase levels were obtained from three experiments performed
in duplicate. *p < 0.05 vs control group (p = 0.0003).
Figure 4 Effect of anacardic acid, dexamethasone and TSA on
PTEN expression in A549 cells. Cells were incubated with
dexamethasone (10
-5 M), the HAT inhibitor anacardic acid (20 μmol/
L) plus dexamethasone (10
-5 M), anacardic acid (20 μmol/L) or TSA(1
μmol/L) for 24 h. The PTEN mRNA level was measured by
quantitative real-time PCR. A representative of three separate
experiments is shown.
#p = 0.006 vs control group; *
#p = 0.0469 vs
Dex+Ana group; **p > 0.05 vs control group.
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induced up-regulation of PTEN mRNA (Figure 4), indicat-
ing that histone acetylation inhibition is involved in the
dexamethasone-induced PTEN expression.
Discussion
OVA-induced asthma mice model is widely used for study
of human asthma because of resemblance pathology and
pathophysiology. Based on this model, we confirmed that
PTEN proteins were under-expressed in mice with OVA-
induced asthma. We also found that treatment of these
mice with dexamethasone resulted in the restoration of
PTEN expression. In vitro studies using human lung epithe-
lial cell A549 revealed that dexamethasone was able to
increase both PTEN promoter activity and gene expression.
Data from all these assays together suggest that the effect of
glucocorticoids on asthma may partly pass through the
PTEN signaling pathway, and that PTEN is a new target
gene involved in the response to dexamethasone. Although
PTEN is a highly conserved gene with more than 80% iden-
tity in the promoter region between Homo sapiens and Mus
musculus,m o r ev a l u a b l ed a t am a yb ed e r i v e df r o mh u m a n s .
Thus, further studies in asthma patients is necessary.
The mechanisms of glucocorticoids in anti-inflamma-
tory treatment for asthma have been investigated exten-
sively. These studies were focused on different targets of
airway or different gene expression, and had provided
some answers regarding the mechanisms. The target
cells studied for glucocorticoid action were mainly air-
way epithelial cells [24], airway smooth muscle cells
[25-29], and inflammatory cells, such as mast cells [30]
and monocytes [31,32]. All these effects could also be
divided into genomic and non-genomic mechanisms
depending on gene expression [7]. More studies will
continue to draw a full picture of the mechanisms of
glucocorticoids in asthma therapy. Here a new mechan-
ism is proposed: glucocorticoids up-regulate PTEN tran-
scription, and PTEN, in turn, inhibits inflammation.
As described above, PTEN maybe a target for asthma
treatment. Regulation of PTEN expression is a key for
this therapy. PTEN regulation has been the subject of
many studies [33-35]. Recent studies revealed that sim-
vastatin, pravastatin, fluvastatin, dietary exposure to the
soy isoflavone genistein (GEN) and phytoestrogens
induce PTEN expression in mammary epithelial cells in
vivo and in vitro [36,37]. Trichostatin A (TSA) could
up-regulate PTEN transcription [23]. The venom of the
scorpion Buthus martensii Karsch upregulates the
expression of PTEN, accompanied by decreased levels of
A k ta n dB a dp h o s p h o r y l a t i o n[ 3 8 ] .H o w e v e r ,T G F - b1,
estrogen, and PRL-3 could down-regulate PTEN expres-
sion [39,40]. There are few reagents that can specifically
regulate PTEN expression in the airways. We believe
more efforts should be made in this area.
With respect to the regulation inflammatory genes, glu-
cocorticoids increase gene expression through alterations
in chromatin structure by histone acetylation and recruit-
ment of RNA polymerase II to the promoter site. This, in
turn, results in the activation of gene transcription [41].
We have tested whether histone acetylation participates in
the regulation of dexamethasone-induced PTEN transcrip-
tion. As shown in Figure 3, the histone acetylase inhibitor
anacardic acid inhibited dexamethasone-induced PTEN
up-regulation in mRNA levels, indicating that histone
acetylase inhibition is associated with transcriptional sti-
mulation of the PTEN gene by dexamethasone. Our
results are supported by the findings of Ito et al. [42] that
high concentrations dexamethasone (>10
-8 M) produce a
time- and concentration-dependent increase in histone
acetylation in A549 cells, resulting in the recruitment of
the activated transcription complex, and the subsequent
increase in the expression of several genes.
The direct effect of glucocorticoids on transcript acti-
vation occurs through binding and activation glucocorti-
coid receptors (GR), which results in the translocation
of glucocorticoid-receptor complexes to the nucleus and
binding to glucocorticoid response elements (GREs) in
the promoter region of target genes [43]. GREs are
short sequences of DNA within the promoter that are
able to bind glucocorticoid-receptor complexes and
therefore regulate gene transcription. The typical DNA
sequence of the GRE is 5’-GGTACAnnnTGTTCT-3’
[44]. However, this typical response element could not
be found in the 5’-upstream region of the PTEN gene.
Several studies have reported several alternative GREs,
in addition to the typical GRE [45-47]. These GREs
have some variability at several nucleotide positions.
Among them, the sequence 5’-TGTNC-3’ was reported
to be a pentamer GRE core sequence [47]. We screened
the promoter region of PTEN (from -778 to -2141) for
homology to this sequence. Two regions with the high-
est homology are at positions -1360 to -1364, and -1604
to -1608, both with the sequence 5’-TGTGC-3’. Further
investigations are necessary to answer whether gluco-
corticoids increase PTEN expression by direct binding
to these two putative GREs in the PTEN promoter
region, or by interfering with the binding of other tran-
scription factors.
In fact, the number of genes directly regulated by glu-
cocorticoids was limited, whereas many genes were
indirectly regulated through an interaction with other
transcription factors and coactivators. Pan et al. reported
that p300 could promote PTEN expression [23]. Wang
et al. reported that dexamethasone treatment increased
SRC-1, CBP and p300 recruited to the PEPCK gene pro-
moter [48]. Recruitment of these transcription factors
promotesd large protein complexes such as RNApoly-
merase II binding to the promoter region. Therefore it
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pated in dexamethasone-induced PTEN regulation.
Here we propose a new signaling pathway of anti-
inflammatory responses. Glucocorticoid up-regulates
PTEN expression, which dephosphorylates the signal
lipid PIP3 and down-regulates PIP3/AKT actions in
turn. As main inflammatory mediators, the downstream
targets are inhibited, thus, asthma could be controlled.
Conclusion
Our study indicates that dexamethasone increases the
expression of PTEN in asthmatic mice and human A549
cells. This induction results from the stimulation of
PTEN transcription, and may involve the increased his-
tone acetylation at the PTEN promoter. A new mechan-
ism of action is proposed for the anti-inflammatory
effect of glucocorticoids in asthma treatment. Specific
regulation of PTEN expression in human airways may
be useful for the treatment of asthma.
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